News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Andres Gomez: This is why we developed a phase 2 study with outpatient ven-aza instead of 7+3
Photo from Andres Gomez/Twitter
Nov 20, 2023, 03:53

Andres Gomez: This is why we developed a phase 2 study with outpatient ven-aza instead of 7+3

Andres Gomez, Associate Professor at the Autonomous University of Nuevo León, Monterrey, Mexico, posted on X/Twitter:

“This is why we developed a phase 2 study with outpatient ven-aza instead of 7+3 and why Yadith Lopez will present a poster comparing pre-post outcomes in the American Society of Hematology 23.

AML in India commentary The Lancet Haematology mirrors Mexico.”

Andres Gomez: This is why we developed a phase 2 study with outpatient ven-aza instead of 7+3

For the article click here.
Source: Andres Gomez/Twitter

American Society of Hematology AML Andres Gomez Autonomous University of Nuevo León cancer OncoDaily Oncology The Lancet Haematology Yadith Lopez
Special Coverage
Blog
Dec 30, 2024, 12:58
Gevorg Tamamyan: ADCO YIA for Survivorship research need everyone's support
Insight
Dec 30, 2024, 12:39
When Diversity Goals Meet Multiregional Trials by Gautam Mehta et al. - FDA Oncology
Blog
Dec 30, 2024, 12:36
Jean Kaseya: No one serving humanity should endure violence
Insight
Dec 30, 2024, 12:33
Patrick Hwu: Why treating neurological disorders like brain tumors is difficult
Insight
Dec 30, 2024, 12:29
Laura Bukavina: No significant link was found between plant-based or animal-based protein intake and bladder cancer risk
Science
Dec 30, 2024, 12:25
Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer
Science
Dec 30, 2024, 12:08
Nicholas Short: Measurable residual disease monitoring in AML
Blog
Dec 30, 2024, 12:06
Michael Hofman: Honoring Felix Feng
Science
Dec 30, 2024, 12:03
Misty Dawn Shields: Rare lung cancers have a paucity of info and they aren’t in first place
Science
Dec 30, 2024, 11:56
Anirban Maitra: The highest cited publication overall is a review on Pancreatic Cancer
Insight
Dec 30, 2024, 11:25
Shane Jacobson: The V Foundation is launching a search for Senior (executive) Leadership Team
Insight
Dec 30, 2024, 11:19
Anirban Maitra: An Open Access review on current status of KRAS inhibitors, resistance drivers and potential combinations